GET DAILY SIGNALSBicara Therapeutics (BCAX) Declines -43.6% as Competitive Headwinds Intensify
Key Takeaways
- Bicara Therapeutics (BCAX) declined roughly 43.6% over the trailing 30 days, driven chiefly by a single-session collapse on October 28, 2026.
- The selloff was triggered by positive Phase 3 data from Genmab for a competing head and neck cancer therapy, sharpening the competitive threat to Bicara's lead candidate.
- Goldman Sachs downgraded BCAX to Sell with an $8 price target, while several other analysts retained Buy or Outperform ratings, reflecting a sharp divergence of opinion.
- Third-quarter 2026 results, reported in early November, showed a wider-than-expected net loss and no revenue, consistent with a clinical-stage biopharmaceutical company.
- Bicara held approximately $497.3 million in cash as of mid-2026, funding operations toward its pivotal FORTIFI-HN01 readout expected in 2027.
- For additional context, explore detailed pages covering Price Targets, Earnings, and Forecast information for BCAX.
Bicara Therapeutics (BCAX) Company Overview and Market Position
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts. The company is focused on developing bifunctional therapies for solid tumors, with a platform designed to target the tumor precisely while delivering a tumor-modulating payload directly to the tumor microenvironment. Its lead program, ficerafusp alfa (formerly BCA101), is a bifunctional antibody that combines an epidermal growth factor receptor (EGFR)-directed monoclonal antibody with a human transforming growth factor beta (TGF-β) ligand trap. Ficerafusp alfa is initially being developed for head and neck squamous cell carcinoma (HNSCC), an area with significant unmet medical need. Because Bicara is pre-revenue, investors follow the stock primarily for its clinical trial milestones, competitive positioning, and cash runway. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Bicara Therapeutics (BCAX) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, BCAX shares fell from a closing level of about $17.34 to a latest price near $9.78, a decline of approximately 43.6%. The move was not gradual: the bulk of the loss occurred in a single session on October 28, 2026, when the stock dropped from a prior close of $17.48 to close near $9.76 on unusually heavy volume. The shares subsequently traded in a volatile range between roughly $7.90 and $10.53.
The longer-term picture is similarly weak. Measured over roughly the last three months, BCAX declined from about $23.63 in mid-August to the latest levels, a drop of more than 55%. This extended slide reflects a steady multi-month downtrend that accelerated sharply with the October catalyst, moving the stock well below its 52-week high and near its 52-week low.
What Drove BCAX Stock Price in the Last 30 Days
The defining event of the period was external rather than company-specific. On October 28, 2026, Genmab announced positive Phase 3 results from its LiGeR-HN1 study, in which petosemtamab combined with pembrolizumab met both primary endpoints in first-line PD-L1-positive recurrent or metastatic HNSCC, demonstrating a statistically significant improvement in overall survival. Because Bicara's ficerafusp alfa is being developed in the same head and neck cancer space, the data intensified competitive pressure on the company's lead program, and BCAX shares plunged more than 40% in a single session on elevated volume.
Analyst reaction amplified the move. Goldman Sachs downgraded BCAX from Neutral to Sell with an $8 price target, citing a dimmer competitive outlook for ficerafusp alfa and framing the market as "winner-takes-all." At the same time, other firms maintained constructive views, including Buy and Outperform ratings with price targets well above the current price, underscoring a wide dispersion of opinion. Separately, Bicara reported third-quarter 2026 results on November 9, posting a net loss per share of $1.04 versus consensus estimates of a $0.85 loss, with no revenue.
What Drove BCAX Stock Performance Over the Last Quarter
The quarterly decline reflects a broader erosion in sentiment that predated the October shock. BCAX traded near the mid-$20s in early August before drifting lower through September, as investors weighed competitive dynamics and the timing of upcoming data in HNSCC. The Genmab readout in late October crystallized those concerns, converting a gradual downtrend into a sharp repricing. The sustained weakness since then indicates that the market is reassessing the probability of commercial success for ficerafusp alfa in an increasingly crowded first-line HNSCC landscape, even as Bicara continues to advance its pivotal FORTIFI-HN01 study.
BCAX Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important catalyst is the Phase 3 FORTIFI-HN01 trial of ficerafusp alfa in first-line recurrent or metastatic HPV-negative HNSCC, with results expected around mid-2027. An interim analysis is anticipated once a specified number of patients complete extended follow-up. Investors will also monitor how the competitive landscape evolves following Genmab's data, including any regulatory or commercial progress for petosemtamab and other HNSCC therapies. Cash management and future financing needs remain a key watch item given the company's pre-revenue status, as does quarterly expense discipline. Analyst rating changes, further clinical updates, and regulatory milestones will likely continue to drive volatility in BCAX shares. From what I see, exploring Tickeron’s AI Trend Prediction Engine offers one way to track potential shifts in sentiment around these milestones.
Exploring Tickeron AI Tools for Market Context
In my own research process, Tickeron’s AI Daily Buy/Sell Signals has proven useful for monitoring how clinical-stage names like BCAX respond to sector-specific news. The platform aggregates algorithmic signals across thousands of tickers, allowing a clearer view of short-term momentum without replacing fundamental analysis. I find it helpful when cross-checking analyst divergence or volume spikes, though results vary by market conditions and should be combined with other due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
BCAX's RSI Oscillator ascends from oversold territory
The RSI Oscillator for BCAX moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 6 similar instances when the indicator left oversold territory. In 6 of the 6 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 20 of 27 cases where BCAX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Momentum Indicator moved above the 0 level on November 11, 2026. You may want to consider a long position or call options on BCAX as a result. In 25 of 34 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for BCAX just turned positive on November 11, 2026. Looking at past instances where BCAX's MACD turned positive, the stock continued to rise in 15 of 20 cases over the following month. The odds of a continued upward trend are 75%.
Following a +5.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where BCAX advanced for three days, in 100 of 124 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
BCAX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for BCAX entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.221) is normal, around the industry mean (3.498). P/E Ratio (-2.818) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. BCAX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement